Actively Recruiting
Evaluation of Safety, Tolerability, and Immune Response to the RSVpreF Vaccine in Adults 60 Years and Older
Led by Pfizer · Updated on 2026-10-09
600
Participants Needed
15
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and immune response to the RSVpreF vaccine in healthy adults aged 60 years and older. This study includes participants from China and the United States, comparing reactions and antibody responses between those receiving RSVpreF and a placebo in China, while all participants in the US receive RSVpreF. The goal is to understand the effects and immune protection that the vaccine may provide to older adults. Participants will receive a single dose of either the RSVpreF vaccine or placebo in China or only RSVpreF in the US. The study includes a screening visit, followed by vaccination at Visit 1. Subsequent follow-ups include a telephone or clinic visit one week later to assess local and systemic reactions, a clinic visit one month after vaccination for health checks and blood tests, and a final telephone or clinic visit six months after vaccination to monitor overall health. Throughout the study, participants will have blood tests at screening China only, on vaccination day, and one month post-vaccination to measure antibody levels. Researchers will monitor local injection site reactions, systemic symptoms, adverse events, and newly diagnosed chronic medical conditions for up to six months. Participants will be involved in electronic diary recording and regular follow-up visits during the approximately six-month participation period.
CONDITIONS
Brief Title
A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here